// App-Quantinova.ai

2895 : An Open-Label Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in the Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL).

Researchers

Presenter

  • Harminder Paul

Principal Investigators

  • Luisa Del Rizzo

  • Lisa W Le

  • Ellen Nong Wei

  • Anthea Lau

  • James B Johnston

  • Spencer B Gibson

  • Michelle Brown

  • Suzanne Trudel

Medical Centers

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Manitoba Institute of Cell Biology, CancerCare Manitoba, Winnipeg, MB, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Chronic Lymphocytic Leukemia

  • Tumor lysis syndrome

  • Arrhythmia

  • Pulmonary embolism

  • Thrombocytopenia

  • Constipation

  • Neutropenia

  • Insomnia

Biomarkers

  • Granulocyte colony-stimulating factor

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Allopurinol

  • Sulfamethoxazole and Trimethoprim

  • ZAP70

  • Filgrastim

Outcome

  • N/A

Study Design

  • open label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved